Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO.

Antigen presentation by major histocompatibility complex class II molecules is essential for antibody production and T cell activation. For most class II alleles, peptide binding depends on the catalytic action of human histocompatibility leukocyte antigens (HLA)-DM. HLA-DO is selectively expressed...

Full description

Bibliographic Details
Main Authors: van Ham, M, van Lith, M, Lillemeier, B, Tjin, E, Grüneberg, U, Rahman, D, Pastoors, L, van Meijgaarden, K, Roucard, C, Trowsdale, J, Ottenhoff, T, Pappin, D, Neefjes, J
Format: Journal article
Language:English
Published: 2000
_version_ 1797085095919616000
author van Ham, M
van Lith, M
Lillemeier, B
Tjin, E
Grüneberg, U
Rahman, D
Pastoors, L
van Meijgaarden, K
Roucard, C
Trowsdale, J
Ottenhoff, T
Pappin, D
Neefjes, J
author_facet van Ham, M
van Lith, M
Lillemeier, B
Tjin, E
Grüneberg, U
Rahman, D
Pastoors, L
van Meijgaarden, K
Roucard, C
Trowsdale, J
Ottenhoff, T
Pappin, D
Neefjes, J
author_sort van Ham, M
collection OXFORD
description Antigen presentation by major histocompatibility complex class II molecules is essential for antibody production and T cell activation. For most class II alleles, peptide binding depends on the catalytic action of human histocompatibility leukocyte antigens (HLA)-DM. HLA-DO is selectively expressed in B cells and impedes the activity of DM, yet its physiological role remains unclear. Cell surface iodination assays and mass spectrometry of major histocompatibility complex class II-eluted peptides show that DO affects the antigenic peptide repertoire of class II. DO generates both quantitative and qualitative differences, and inhibits presentation of large-sized peptides. DO function was investigated under various pH conditions in in vitro peptide exchange assays and in antigen presentation assays using DO(-) and DO(+) transfectant cell lines as antigen-presenting cells, in which effective acidification of the endocytic pathway was prevented with bafilomycin A(1), an inhibitor of vacuolar ATPases. DO effectively inhibits antigen presentation of peptides that are loaded onto class II in endosomal compartments that are not very acidic. Thus, DO appears to be a unique, cell type-specific modulator mastering the class II-mediated immune response induced by B cells. DO may serve to increase the threshold for nonspecific B cell activation, restricting class II-peptide binding to late endosomal compartments, thereby affecting the peptide repertoire.
first_indexed 2024-03-07T02:04:15Z
format Journal article
id oxford-uuid:9e6cd96b-56f7-4fb4-9bf1-a0ea8df52a6d
institution University of Oxford
language English
last_indexed 2024-03-07T02:04:15Z
publishDate 2000
record_format dspace
spelling oxford-uuid:9e6cd96b-56f7-4fb4-9bf1-a0ea8df52a6d2022-03-27T00:50:00ZModulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:9e6cd96b-56f7-4fb4-9bf1-a0ea8df52a6dEnglishSymplectic Elements at Oxford2000van Ham, Mvan Lith, MLillemeier, BTjin, EGrüneberg, URahman, DPastoors, Lvan Meijgaarden, KRoucard, CTrowsdale, JOttenhoff, TPappin, DNeefjes, JAntigen presentation by major histocompatibility complex class II molecules is essential for antibody production and T cell activation. For most class II alleles, peptide binding depends on the catalytic action of human histocompatibility leukocyte antigens (HLA)-DM. HLA-DO is selectively expressed in B cells and impedes the activity of DM, yet its physiological role remains unclear. Cell surface iodination assays and mass spectrometry of major histocompatibility complex class II-eluted peptides show that DO affects the antigenic peptide repertoire of class II. DO generates both quantitative and qualitative differences, and inhibits presentation of large-sized peptides. DO function was investigated under various pH conditions in in vitro peptide exchange assays and in antigen presentation assays using DO(-) and DO(+) transfectant cell lines as antigen-presenting cells, in which effective acidification of the endocytic pathway was prevented with bafilomycin A(1), an inhibitor of vacuolar ATPases. DO effectively inhibits antigen presentation of peptides that are loaded onto class II in endosomal compartments that are not very acidic. Thus, DO appears to be a unique, cell type-specific modulator mastering the class II-mediated immune response induced by B cells. DO may serve to increase the threshold for nonspecific B cell activation, restricting class II-peptide binding to late endosomal compartments, thereby affecting the peptide repertoire.
spellingShingle van Ham, M
van Lith, M
Lillemeier, B
Tjin, E
Grüneberg, U
Rahman, D
Pastoors, L
van Meijgaarden, K
Roucard, C
Trowsdale, J
Ottenhoff, T
Pappin, D
Neefjes, J
Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO.
title Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO.
title_full Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO.
title_fullStr Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO.
title_full_unstemmed Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO.
title_short Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO.
title_sort modulation of the major histocompatibility complex class ii associated peptide repertoire by human histocompatibility leukocyte antigen hla do
work_keys_str_mv AT vanhamm modulationofthemajorhistocompatibilitycomplexclassiiassociatedpeptiderepertoirebyhumanhistocompatibilityleukocyteantigenhlado
AT vanlithm modulationofthemajorhistocompatibilitycomplexclassiiassociatedpeptiderepertoirebyhumanhistocompatibilityleukocyteantigenhlado
AT lillemeierb modulationofthemajorhistocompatibilitycomplexclassiiassociatedpeptiderepertoirebyhumanhistocompatibilityleukocyteantigenhlado
AT tjine modulationofthemajorhistocompatibilitycomplexclassiiassociatedpeptiderepertoirebyhumanhistocompatibilityleukocyteantigenhlado
AT grunebergu modulationofthemajorhistocompatibilitycomplexclassiiassociatedpeptiderepertoirebyhumanhistocompatibilityleukocyteantigenhlado
AT rahmand modulationofthemajorhistocompatibilitycomplexclassiiassociatedpeptiderepertoirebyhumanhistocompatibilityleukocyteantigenhlado
AT pastoorsl modulationofthemajorhistocompatibilitycomplexclassiiassociatedpeptiderepertoirebyhumanhistocompatibilityleukocyteantigenhlado
AT vanmeijgaardenk modulationofthemajorhistocompatibilitycomplexclassiiassociatedpeptiderepertoirebyhumanhistocompatibilityleukocyteantigenhlado
AT roucardc modulationofthemajorhistocompatibilitycomplexclassiiassociatedpeptiderepertoirebyhumanhistocompatibilityleukocyteantigenhlado
AT trowsdalej modulationofthemajorhistocompatibilitycomplexclassiiassociatedpeptiderepertoirebyhumanhistocompatibilityleukocyteantigenhlado
AT ottenhofft modulationofthemajorhistocompatibilitycomplexclassiiassociatedpeptiderepertoirebyhumanhistocompatibilityleukocyteantigenhlado
AT pappind modulationofthemajorhistocompatibilitycomplexclassiiassociatedpeptiderepertoirebyhumanhistocompatibilityleukocyteantigenhlado
AT neefjesj modulationofthemajorhistocompatibilitycomplexclassiiassociatedpeptiderepertoirebyhumanhistocompatibilityleukocyteantigenhlado